Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

BACKGROUND: In melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no FDA-approved targeted therapies exist for BRAF-inhibitor-resistant BRAF(V...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155088/
https://www.ncbi.nlm.nih.gov/pubmed/25142146
http://dx.doi.org/10.1186/1476-4598-13-194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155088/
https://www.ncbi.nlm.nih.gov/pubmed/25142146
http://dx.doi.org/10.1186/1476-4598-13-194

Ejemplares similares